A clinical flow chart for the treatment resistant smoker
Sponsored Links
This presentation is the property of its rightful owner.
1 / 12

A Clinical Flow-Chart for the “Treatment-Resistant Smoker” PowerPoint PPT Presentation

  • Uploaded on
  • Presentation posted in: General

A Clinical Flow-Chart for the “Treatment-Resistant Smoker”. Renee Bittoun. Background. Most smokers want to quit (Fong, 2004) Very few do not (about 6% in Australia) Many/most fail at quit attempts with or without pharmacotherapies (Cohrane Reviews).

Download Presentation

A Clinical Flow-Chart for the “Treatment-Resistant Smoker”

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript

A Clinical Flow-Chart for the “Treatment-Resistant Smoker”

Renee Bittoun


  • Most smokers want to quit (Fong, 2004)

  • Very few do not (about 6% in Australia)

  • Many/most fail at quit attempts with or without pharmacotherapies (Cohrane Reviews)

WHO: International Framework Convention on Tobacco Control, 2005

The Framework Convention on Tobacco Control (FCTC): Article 1. Section D.

harmreduction strategies

to improve the health of a population by eliminating or reducing their consumption of tobacco products

Background to harm-reduction

  • Using pharmacotherapies while smoking  inhaled toxicants (Fagerstrom,2002)

  • Potential gateway to quitting (Fagerstrom, 2005; Hughes, 2005)

  • Harm-reduction agenda a softer,

    not the “stop smoking or you’ll die”

    dogma of abrupt quitting (Warner, 2005)

Benefits of using NRT for Harm-reduction and Temporary Abstinence

  • Relief of craving and other withdrawal symptoms

  • Reduced cigarette consumption and prevention of compensatory smoking

  • Smokers may learn that they can manage without tobacco for several hours 

     motivation to quit

Back ground to combination therapies

  • Combination therapies show good outcomes in “hard-to-treat” smokers (Bittoun, 2005)

  • A flow chart has been developed for clinicians that directs management of the difficult smoking patient: from the disinterested to the poor responders

  • The flow-chart shows increasing therapies as required, using clinical signs and symptoms (withdrawal) to guide treatment choices


  • Apply strategies, both NRT and smoking---to mental health/intellectually disabled smokers

  • 90% comorbid COPD patients using combination/harm reduction

Some Results

  • 16% no pharmacotherapies

  • 16% oral NRT (gum,lozenge)

  • 16% on 2 X 21mg patch

  • 21% on 2 X 21mg patch plus oral NRT

  • 5% on 3 X 21mg patch

  • 5% on Bupropion

  • 1% on Bupropion plus 21mg patch

  • 20% lost to follow-up


  • Many do not have the “wherewithal” to quit as:-

    too hard (overwhelming withdrawals)

    pharmacotherapies too expensive

    limited understanding of withdrawals

  • Akrasia (lack of will-power, inability to reconcile your want/need with your action, loss of control=addictive behaviour) (Aristotle, 4BCE; Heather, 1998; Ainslie, 2001)

  • Harm-reduction may be a softer option


  • Don’t abandon the “hard-to-treat” “can’t quit” smoker

  • Develop a hierarchy of strategies for smokers that begins with permanent cessation using increasing combinations as required but----

  • Consider harm-reduction for resistant smokers

  • ?? Unethical to exclude recommending harm reduction behaviours to resistant smokers as an alternative to the “Quit or You’ll Die” Dogma.

  • Login